Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA

SpeedWeed

MAY 24, 2021

The Drug Enforcement Administration made a milestone announcement earlier this month with the news that the DEA will begin granting marijuana cultivation licenses to various third-party applicants, significantly expanding medical and scientific cannabis research in the United States.

DEA

The Blunt Truth

MAY 15, 2020

We’ve got an update on the latest Montana legalization developments. The news on access to loans and other support from the Small Business Administration was less rosy. marijuana research. The big news this week is that cannabis banking is included in the latest federal relief bill. SBA funds, however, are not.

Banking

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The FDA refers to this program as the expanded access program on their website. Patients Are Not In This Alone.

Therapy

SpeedWeed

AUGUST 7, 2021

Democratic leaders in both chambers of Congress have come up with a new plan that would make it easier for scientists to access high-quality cannabis for research. . But the bill also includes additional provisions to ensure that scientists will be able to use high-quality cannabis to conduct this research.

DEA

Canna Law Blog

MARCH 4, 2020

With respect to ketamine infusion therapy (which is the prime time attraction of ketamine clinics), the medical research based promise is for treatment of chronic neuropathic pain, chronic pain (instead of opioids), and various medication-resistant mental health disorders, including depression, bi-polar disorder, and PTSD (among others).

Legalization

Cannabis Law Report

DECEMBER 15, 2021

Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybin-containing mushrooms for authorized research purposes. “Having a supply partner that gives us access to the rapidly growing U.S. “With their track-record of working with the U.S.

Supply Chain

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials

Veriheal

DECEMBER 27, 2022

Let’s dive into what the research says about these promising new findings and how they might advance the field of psychedelic research. Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. The subjective nature of self-reported data can plague research.

Research and Development

Cannabis Law Report

JULY 1, 2021

On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation. POPLAR will publish original law and policy research. What barriers exist to conducting psychedelics research?

Law

The Cannigma

MAY 16, 2025

So while a cannabis business can join their local chamber of commerce, a patient in hospice can be denied access to medical cannabis. The unstable legality of federal protections for medical cannabis, which solely come from an amendment to the DOJ and DEAs budget that has to pass every year, threatens our progress. Make it make sense.

Policy

Veriheal

MARCH 6, 2024

Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. The other big change that comes with rescheduling is an increase in cannabis research opportunities. billion in excess taxes when compared to non-cannabis businesses.

Research and Development

Veriheal

AUGUST 24, 2022

If passed, the Department of Regulatory Agencies would be required to develop rules that would allow for therapeutic psychedelic programs at licensed healing centers for adults to receive psychedelic treatments by a trained facilitator. Research and Testimonials Point to Psychedelics’ Therapeutic Benefits.

Legalization

MedicalJane

JUNE 29, 2018

On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree. The Next Move Is On The DEA. FDA Grants Approval of Epidiolex.

Clinical Trials

Cannabis Law Report

JULY 9, 2021

Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level. 360bbb-0a.

Law

Cannabis Law Report

JANUARY 23, 2020

This paper shall give a condensed overview over the status quo in Thailand and the potential emerging from the ongoing developments.” This paper shall give a condensed overview over the status quo in Thailand and the potential emerging from the ongoing developments. $16. It can be downloaded at: [link]. cannabis programm. $4b.

Research and Development

Veriheal

JUNE 24, 2021

health official reportedly slammed “ongoing federal restrictions that are inhibiting research into marijuana”. The Senator stated that the NIH has been reporting on “potentially promising peer-reviewed clinical research” and asked for an update on how the NIH was planning to proceed and navigate issues. .

Research and Development

Cannabis Law Report

APRIL 21, 2022

MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . The full statement.

Clinical Trials

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.

Clinical Trials

Veriheal

DECEMBER 1, 2020

When it comes to scientific research and the way of Delta-8-THC, it is scarce. The DEA is Already Interfering. In August of this year, little to most people’s knowledge, the DEA continued their draconian stance against cannabis by proposing that THC derivatives also be classified as schedule one controlled substances.

THC

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Watch Video: The Press Release. NEWS PROVIDED BY. Numinus Wellness Inc. .

Clinical Trials

Sensi Seeds

NOVEMBER 28, 2018

But in an email correspondence conducted as research for this article, EFSA denies issuing any statement in relation to CBD in Spain. Food and Drug Administration (FDA) earlier this year, and convince the DEA to reclassify CBD from a Schedule I (most restrictive category) to a Schedule V drug (least restrictive category.)

CBD

Cannabis Law Report

AUGUST 12, 2022

Obtaining DEA License to Grow Psilocybin Mushrooms. This panel would explore topics such as the ethical implications of psychedelic-based drug development and patenting, as well as the debate over producing and marketing natural versus synthetic psychedelics. Here are some psychedelics panel options: .

Research and Development

Cannabis Law Report

JUNE 15, 2021

. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.

Decriminalization

Cannabis Law Report

SEPTEMBER 1, 2021

3] Further, notwithstanding the determination of the Drug Enforcement Administration (DEA), which is required to defer to the Department of Health and Human Services’ assessment that cannabis has no acceptable medical utility, 37 states and four territories have enacted laws allowing for the medical use of cannabis products. [4] Gordon Gray.

Policy

SMPL

AUGUST 14, 2019

That includes a lack of access to financial services that lead such companies to operate on a largely cash basis, making them targets for crime. The final part of the resolution discusses the need to support research into cannabis. One area that could be quickly improved is in the sourcing of research-grade marijuana.

Policy

Cannabis Info

OCTOBER 4, 2019

Cannabis and cannabinoids are not a tiny project — one compound for one disease — however, I show that it is really a very, very wide field of research,” Mechoulam stated. “We Demetrix is licensed by the DEA to do analysis with pure cannabinoid compounds. “Collaboration is absolutely a necessity.

Cannabinoids

Kind Meds (Cannabis Education Blog)

SEPTEMBER 4, 2019

While the FDA continues to choke the progression of research and scientific developments regarding marijuana, it simultaneously cracks down on the big players of our industry. This ease of accessibility culture has paved the fierce competition in the edibles market, for example. Here’s why. Think of Uber and Lyft.

Dispensary

Cannabis Law Report

JULY 14, 2021

“Closing the door on broadly supported incremental reforms like the SAFE Banking Act while the Senate seeks compromise on farther-reaching bills hurts the possibilities for consensus and ignores the very real needs of small business operators who have repeatedly said that access to banking services and traditional lending is an existential issue.

Legislation

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and Cannabinoids: Health, Research and Regulatory Considerations (Position Paper). Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. This process should also ensure appropriate funding allocated for this research.

Cannabinoids

The Joint Blog

JUNE 4, 2021

Believe it or not, you actually need a license to do meaningful research on marijuana due to the fact that the United States Drug Enforcement Agency (DEA) has limited its access. The DEA feels that marijuana, being a schedule I drug, could be misused like other drugs within that category and could be dangerous.

Conditions

Cannabis Law Report

JULY 30, 2019

Beasley is forced by default to expand her knowledge base through scientific facts that warrant closer inspection and through accessible existing research, with few current cannabis case studies. Most reliable medical cannabis research filters into the U.S. through international sources, namely Israel. . Federal Register. .

Marijuana

Cannabis Law Report

AUGUST 6, 2021

Operating expenses : Total SG&A (“SG&A”) expenses in Q1 2022 declined by 17% versus Q1 2021, driven by year-over-year reductions in General & Administrative (“G&A”) and Research and Development (“R&D”) expenses partially offset by an increase in Sales & Marketing (“S&M”) expenses. Webcast Information.

Vaping

Kind Meds (Cannabis Education Blog)

SEPTEMBER 4, 2019

While the FDA continues to choke the progression of research and scientific developments regarding marijuana, it simultaneously cracks down on the big players of our industry. This ease of accessibility culture has paved the fierce competition in the edibles market, for example. Here’s why. Think of Uber and Lyft.

Marijuana

Cannabis Law Report

APRIL 14, 2022

Although research is still underway, the effects of both short- and long-term exposure to pesticides by consuming (i.e., pursuant to Drug Enforcement Agency (DEA) or state-level programs). by eating or smoking cannabis) are unknown. Water resource depletion has been a concern at both outdoor and indoor grow operations.

Environment

Cannabis Law Report

JUNE 1, 2021

Operating expenses : Total SG&A (“SG&A”) expenses in Q4 2021 declined by 25% versus Q4 2020, driven by year-over-year reductions in Sales & Marketing, and Research and Development (“R&D”) expenses. A replay will be accessible by webcast until 11:59 PM ET on August 30, 2021 at: [link].

Data